The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
暂无分享,去创建一个
M. Lazar | R. DuBois | J. Brockman | Bandaru S. Reddy | B. Reddy | S. L. Krakow | R. Gupta | Rajnish K. Gupta | R. Dubois | Rajnish K. Gupta
[1] A. Kato,et al. Colorectal cancer and non-steroidal anti-inflammatory drugs. , 2000, Acta pharmacologica Sinica.
[2] R. DuBois,et al. Aspirin use and potential mechanisms for colorectal cancer prevention. , 1997, The Journal of clinical investigation.
[3] M. Jimenez-Linan,et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.
[4] J. Morrow,et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.
[5] S. Tafuri,et al. Regulation of Peroxisome Proliferator-activated Receptor γ Activity by Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.
[6] R. DuBois,et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Lazar,et al. Transcriptional Activation by Peroxisome Proliferator-activated Receptor γ Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site* , 1997, The Journal of Biological Chemistry.
[8] A. Watson,et al. Lipid metabolism and APC: implications for colorectal cancer prevention , 1997, The Lancet.
[9] B. Spiegelman,et al. Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.
[10] G. Zhou,et al. Insulin- and Mitogen-activated Protein Kinase-mediated Phosphorylation and Activation of Peroxisome Proliferator-activated Receptor γ* , 1996, The Journal of Biological Chemistry.
[11] Raymond L. White,et al. Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2 , 1996, Cell.
[12] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[13] R. DuBois,et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. , 1996, Gastroenterology.
[14] B. Spiegelman,et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.
[15] R. White,et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Lazar,et al. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma , 1996, Molecular and cellular biology.
[17] R. DuBois,et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.
[18] M. Schuler. Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.
[19] J. Lehmann,et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.
[20] B. Spiegelman,et al. 15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.
[21] Kai Yu,et al. Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.
[22] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[23] S Jothy,et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.
[24] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[25] E. Rimm,et al. Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.
[26] M. Lazar,et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.
[27] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[28] R. DuBois,et al. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. , 1994, The American journal of physiology.
[29] S. H. Brown,et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. , 1994, Archives of internal medicine.
[30] J. Morrow,et al. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. , 1994, The Journal of clinical investigation.
[31] C. Williams,et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis , 1993, The British journal of surgery.
[32] G. Kelloff,et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. , 1993, Carcinogenesis.
[33] J. Baron,et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. , 1993, Journal of the National Cancer Institute.
[34] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[35] M. Thun,et al. Aspirin use and risk of fatal cancer. , 1993, Cancer research.
[36] F. DeRubertis,et al. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. , 1992, Carcinogenesis.
[37] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[38] G. Kelloff,et al. Chemoprevention of Colon Carcinogenesis by Dietary Administration of Piroxicam, α-Difluoromethylornithine, 16α-Fluoro-5-androsten-17-one, and Ellagic Acid Individually and in Combination , 1991 .
[39] Jayashree,et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. , 1990, Cancer research.
[40] W. Waddell,et al. Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.
[41] J. B. Kim,et al. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. , 1996, Science.
[42] G. Kelloff,et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. , 1991, Cancer research.